Axsome Therapeutics, Inc. (LON:0HKF)
London
· Delayed Price · Currency is GBP · Price in USD 104.17
-0.74 (-0.71%)
At close: Jul 2, 2025
Axsome Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Net Income | -278.27 | -287.22 | -239.24 | -187.13 | -130.4 | -102.9 | Upgrade
|
Depreciation & Amortization | 8.26 | 7.96 | 6.83 | 4.4 | 0.08 | 0.08 | Upgrade
|
Other Amortization | 2.69 | 2.64 | 2.57 | 1.48 | 1.08 | 0.79 | Upgrade
|
Asset Writedown & Restructuring Costs | - | - | - | - | - | 7.16 | Upgrade
|
Stock-Based Compensation | 88.34 | 85.22 | 62.62 | 37.73 | 20.8 | 14.76 | Upgrade
|
Other Operating Activities | 30.11 | 29.09 | 50.52 | 3.34 | -0.1 | 1.26 | Upgrade
|
Change in Accounts Receivable | -59.96 | -47.18 | -57.12 | -37.7 | - | - | Upgrade
|
Change in Inventory | 0.6 | 0.74 | -8.16 | -1.33 | - | - | Upgrade
|
Change in Accounts Payable | 31.87 | 31.32 | 2.07 | 25.46 | -0.36 | 2.56 | Upgrade
|
Change in Other Net Operating Assets | 58.05 | 49.02 | 34.81 | 37.24 | 0.68 | -2.15 | Upgrade
|
Operating Cash Flow | -118.32 | -128.41 | -145.08 | -116.51 | -108.23 | -78.46 | Upgrade
|
Capital Expenditures | -0.51 | -0.27 | -0.58 | -0.7 | -0.31 | -0.05 | Upgrade
|
Cash Acquisitions | - | - | - | -53 | - | - | Upgrade
|
Investing Cash Flow | -0.51 | -0.27 | -0.58 | -53.7 | -0.31 | -0.05 | Upgrade
|
Long-Term Debt Issued | - | - | 85 | 45 | - | 50 | Upgrade
|
Long-Term Debt Repaid | - | -0.99 | - | - | - | -21.66 | Upgrade
|
Total Debt Repaid | -1.23 | -0.99 | - | - | - | -21.66 | Upgrade
|
Net Debt Issued (Repaid) | -1.23 | -0.99 | 85 | 45 | - | 28.34 | Upgrade
|
Issuance of Common Stock | 105.65 | 71.46 | 271.17 | 250.01 | 11.84 | 15.18 | Upgrade
|
Repurchase of Common Stock | -6.67 | -3.95 | -1.84 | -0.53 | -0.18 | - | Upgrade
|
Other Financing Activities | -9.45 | -8.68 | -23.32 | -9.9 | -0.53 | -1.1 | Upgrade
|
Financing Cash Flow | 88.3 | 57.84 | 331.01 | 284.58 | 11.13 | 42.41 | Upgrade
|
Net Cash Flow | -30.53 | -70.84 | 185.35 | 114.37 | -97.4 | -36.09 | Upgrade
|
Free Cash Flow | -118.83 | -128.68 | -145.66 | -117.21 | -108.53 | -78.5 | Upgrade
|
Free Cash Flow Margin | -27.50% | -33.36% | -53.83% | -234.25% | - | - | Upgrade
|
Free Cash Flow Per Share | -2.46 | -2.69 | -3.21 | -2.88 | -2.88 | -2.11 | Upgrade
|
Cash Interest Paid | 19.38 | 19.69 | 16.73 | 7.69 | 4.63 | 2.1 | Upgrade
|
Levered Free Cash Flow | -20.98 | -28.71 | -78.72 | -42.36 | -59.52 | -47.37 | Upgrade
|
Unlevered Free Cash Flow | -18.72 | -27.25 | -77.26 | -39.26 | -57.04 | -46.55 | Upgrade
|
Change in Net Working Capital | -34.71 | -37.62 | 31.82 | -28.94 | -0.33 | -0.59 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.